Finance

Lists
Why is ARTV up 2,06%?
Dive Deeper
ARTV:NASDAQ
Artiva Biotherapeutics Inc
6,94 US$
+2,06%
(+0,14) 1D
9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARTV...
Open
6,84 US$
High
7,14 US$
Low
6,77 US$
Mkt. cap
339,30 მლნ.
Avg. vol.
454,25 ათ.
Volume
0,00
52-wk high
14,53 US$
52-wk low
2,71 US$
EPS
-3,31 US$
Shares outstanding
48,89 მლნ.
No. of employees
115
Open
6,84 US$
High
7,14 US$
Low
6,77 US$
Mkt. cap
339,30 მლნ.
Avg. vol.
454,25 ათ.
Volume
0,00
52-wk high
14,53 US$
52-wk low
2,71 US$
EPS
-3,31 US$
Shares outstanding
48,89 მლნ.
No. of employees
115
News stories
From web sources and news partners
Investing.com Nigeria
Investing.com Nigeria
·
17 საათის წინ
Form 144 ARTIVA BIOTHERAPEUTICS INC For: 11 October By Investing.com
About Artiva Biotherapeutics Inc
CEO-
Employees115
Founded2019
Headquarters-
Sector-
Websiteartivabio.com
Analyst ratings
Based on 3 analysts giving stock ratings to ARTV in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ARTV in the last 3 months.
Highest
Current 6,94 US$
41,00 US$ (+490,78%)
Average
38,00 US$ (+447,55%)
Lowest
35,00 US$ (+404,32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gil Blum
Needham
Buy
Maintained
41,00 US$
+490,8%
10/01/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
35,00 US$
+404,3%
10/01/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
40,00 US$
+476,4%
05/25/2026
Unknown Analyst
Jefferies
Buy
Maintained
23,00 US$
+231,4%
05/21/2026
Martin Fan
Wedbush
Buy
Maintained
40,00 US$
+476,4%
05/21/2026
David Nierengarten
Wedbush
Buy
Maintained
40,00 US$
+476,4%
05/21/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17,63 მლნ.
16,99 მლნ.
19,31 მლნ.
21,92 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,26 მლნ.
4,94 მლნ.
5,12 მლნ.
4,96 მლნ.
Operating expense
22,90 მლნ.
21,93 მლნ.
24,43 მლნ.
26,89 მლნ.
Total operating expenses
22,90 მლნ.
21,93 მლნ.
24,43 მლნ.
26,89 მლნ.
Operating income
-22,90 მლნ.
-21,93 მლნ.
-24,43 მლნ.
-26,89 მლნ.
Other non operating income
-3,00 ათ.
-1,88 მლნ.
2,00 ათ.
-1,00 ათ.
EBT including unusual items
-21,53 მლნ.
-20,77 მლნ.
-23,52 მლნ.
-25,00 მლნ.
EBT excluding unusual items
-21,53 მლნ.
-22,65 მლნ.
-23,52 მლნ.
-25,00 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21,53 მლნ.
-20,77 მლნ.
-23,52 მლნ.
-25,00 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,88
-0,84
-0,95
-0,63
Interest and investment income
1,37 მლნ.
1,16 მლნ.
912,00 ათ.
1,89 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,37 მლნ.
1,16 მლნ.
912,00 ათ.
1,89 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,24 მლნ.
-21,27 მლნ.
-23,76 მლნ.
-26,20 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები